Lamotrigine and Bupropion Interaction Guidelines

Critical Safety Considerations

The National Comprehensive Cancer Network recommends careful patient selection and monitoring when combining lamotrigine and bupropion due to the potential for additive seizure risk and neuropsychiatric effects 1, 2, 3
Absolute contraindications for bupropion include active seizure disorder, brain metastases, stroke history, or any condition that increases seizure risk, as stated by the National Comprehensive Cancer Network and Gastroenterology guidelines 1, 2
Bupropion carries a 0.1% seizure risk at therapeutic doses, which increases with higher doses, according to Praxis Medical Insights 3
The Gastroenterology guideline recommends avoiding bupropion in patients with eating disorders due to elevated seizure risk 2
The National Comprehensive Cancer Network and Praxis Medical Insights suggest monitoring closely for worsening depression, suicidal ideation, and behavioral changes, particularly in patients under 24 years old 1, 2, 3
Bupropion carries a black box warning for suicidal behavior/ideation in young adults with depression, as noted by Praxis Medical Insights 3

The Gastroenterology guideline recommends checking blood pressure and heart rate regularly, as bupropion can cause elevations 2, 3
Bupropion is contraindicated in uncontrolled hypertension, according to Gastroenterology and Praxis Medical Insights guidelines 2, 3

The American Academy of Family Physicians recommends initiating bupropion at 150 mg once daily, increasing to 150 mg twice daily after 3-7 days if tolerated, with a maximum dose of 300 mg/day 1, 7
The American Academy of Family Physicians suggests not taking the second bupropion dose after 3 PM to minimize insomnia risk 7

The Gastroenterology guideline recommends avoiding concurrent MAO inhibitor use or within 14 days of discontinuation 2
The Gastroenterology and Praxis Medical Insights guidelines suggest avoiding concurrent opioid therapy if using the naltrexone-bupropion formulation 2, 3
The Gastroenterology guideline recommends dose reduction in moderate to severe hepatic impairment 4, 5
The Gastroenterology guideline recommends avoiding use in end-stage renal disease 4, 5